Want to see GALT full AI Analyst Report?
Top Page
Galectin Therapeutics
(NASDAQ:GALT)
Select Model
Select Model
Rating:47Neutral
Price Target:
$4.50
▼(-21.19% Downside)
Action:Reiterated
Date:06/27/26
Overall score is weighed down primarily by weak financial performance (no revenue, ongoing losses/cash burn, and a highly stressed balance sheet with negative equity and high debt). Technicals provide some support due to strong upside momentum, but overbought signals raise near-term risk. The FDA Phase 3 alignment is a meaningful positive catalyst, while valuation remains constrained by lack of profitability and no dividend yield support.
Positive Factors
Regulatory de‑risking: FDA Phase 3 alignment
Securing FDA agreement on endpoints and trial design materially reduces regulatory uncertainty for belapectin. A clear single‑study full‑approval pathway and accepted assessment methodology improve trial credibility, make the program more partnerable, and raise the long‑term chance of regulatory success.
Negative Factors
Highly stressed balance sheet
Deeply negative equity paired with substantial debt sharply constrains financial flexibility. This capital structure raises refinancing and covenant risk, limits the company's ability to self‑fund a Phase 3, and increases the likelihood that strategic execution will require dilutive financings or onerous partner terms.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory de‑risking: FDA Phase 3 alignment
Securing FDA agreement on endpoints and trial design materially reduces regulatory uncertainty for belapectin. A clear single‑study full‑approval pathway and accepted assessment methodology improve trial credibility, make the program more partnerable, and raise the long‑term chance of regulatory success.
Read all positive factors
Galectin Therapeutics (GALT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$297.01M
Dividend YieldN/A
Average Volume (3M)331.12K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue GrowthN/A
EPS Growth43.38%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.41
Shares Outstanding65,856,895
10 Day Avg. Volume281,636
30 Day Avg. Volume331,121
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-16.33
Forecast
1Y Price Target
$11.00Price Target Upside92.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Galectin Therapeutics Business Overview & Revenue Model
Company Description
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship...
How the Company Makes Money
As a clinical-stage biotechnology company, Galectin Therapeutics does not have publicly established, recurring product revenue from commercialized drugs; its business model is primarily centered on advancing drug candidates through clinical trials...
Galectin Therapeutics Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
3
Very Negative
Cash Flow
7
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -23.45M | -41.47M | -38.24M | -37.71M | -30.00M |
| Net Income | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M |
Balance Sheet | |||||
| Total Assets | 19.53M | 17.50M | 28.20M | 21.29M | 41.83M |
| Cash, Cash Equivalents and Short-Term Investments | 17.72M | 15.12M | 25.66M | 18.59M | 39.65M |
| Total Debt | 133.76M | 106.25M | 71.81M | 39.87M | 29.06M |
| Total Liabilities | 145.73M | 120.56M | 88.44M | 53.48M | 39.21M |
| Stockholders Equity | -126.19M | -103.07M | -60.24M | -32.19M | 2.62M |
Cash Flow | |||||
| Free Cash Flow | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
| Operating Cash Flow | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 26.48M | 31.23M | 40.03M | 10.00M | 36.81M |
Galectin Therapeutics Technical Analysis
Positive
5.71
Price Trends
2.72
Positive
2.75
Positive
3.71
Positive
Market Momentum
0.58
Negative
71.41
Negative
72.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GALT, the sentiment is Positive. The current price of 5.71 is above the 20-day moving average (MA) of 3.28, above the 50-day MA of 2.72, and above the 200-day MA of 3.71, indicating a bullish trend. The MACD of 0.58 indicates Negative momentum. The RSI at 71.41 is Negative, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GALT.
Galectin Therapeutics Risk Analysis
Galectin Therapeutics disclosed 37 risk factors in its most recent earnings report. Galectin Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galectin Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $715.71M | -8.50 | -32.33% | ― | ― | 38.99% | |
56 Neutral | $1.31B | -7.37 | -51.34% | 14.68% | ― | 94.97% | |
53 Neutral | $671.64M | 7.14 | -54.39% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $297.01M | -11.08 | 21.05% | ― | ― | 43.38% | |
44 Neutral | $228.39M | -1.91 | -55.97% | ― | -45.50% | -35.63% | |
44 Neutral | $170.76M | -1.67 | -80.56% | ― | ― | 59.42% |
* Healthcare Sector Average
GALT
Galectin Therapeutics
4.51
2.36
109.77%
OMER
Omeros
9.28
6.20
201.30%
VYGR
Voyager Therapeutics
3.78
0.74
24.34%
TECX
Tectonic Therapeutic
37.93
17.15
82.53%
JBIO
Jade Biosciences
21.51
11.06
105.84%
TNYA
Tenaya Therapeutics
0.79
0.20
34.82%
Galectin Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Galectin Advances Belapectin to Phase 3 After FDA Alignment
Positive
Jun 23, 2026
On June 23, 2026, Galectin Therapeutics reported positive outcomes from an in‑person Type C meeting with the U.S. Food and Drug Administration, securing agreement on the primary endpoint, trial design and regulatory pathway for Phase 3 devel...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.